Aim immunotech announces strategic sale of new brunswick, new jersey facility to allocate additional resources to advance pipeline

Ocala, fla., march 07, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced the sale of its facility located in new brunswick, new jersey for a purchase price of $3.9 million.
AIM Ratings Summary
AIM Quant Ranking